Remdesivir in COVID-19: A Retrospective Analysis of Remdesivir Effectiveness and the Relation with Blood Type Variation

identify the profile of the effectiveness of Remdesivir (RDV) therapy and its relationship to blood type variations in COVID-19 patients at Universitas Indonesia Hospital (RSUI).Methods: Variations in blood types were examined for their influence on the effectiveness in Covid-19 infected patients with RDV as an antiviral treatment. Data for this study were acquired at RSUI using a retrospective cross-sectional method. The sample is infected patients with COVID-19 from January 2021 to December 2021 who received RDV therapy. The parameters of the effectiveness of the treatment was a reduction of minimally 2 points on the WHO Clinical Progression Scale after 14 days of Remdesivir administration.Results: RDV effectiveness percentage shows 57.5% of patients experienced clinical improvement. The analysis results of the effect of blood type variations on clinical outcomes significantly affect the effectiveness of RDV therapy (OR: 1.705, 95% CI: 1.091–2.665; p = 0.019) but insignificant in terms of mortality status (OR: 0.654, 95% CI: 0.383–1.117; p = 0.120).Conclusion: Blood type variations significantly affected the effectiveness of RDV therapy in infected COVID-19 patients.